Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage
When I teach interpretation of the medical literature to students, I remind them that if you think something sounds too good to be true, it probably is
Increased serum transferrin receptor concentrations in Friedreich ataxia
In part this was because a set of experiments conducted in dogs between 1939 and 1940 cast doubt about the existence of incretin
BPC-157 remains a research compound without regulatory approval